Meeting
2020 ASCO Virtual Scientific Program
Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).
Authors
Scot Anthony Niglio
National Cancer Institute, National Institutes of Health, Bethesda, MD
Scot Anthony Niglio , Daniel da Motta Girardi , Amir Mortazavi , Primo Lara Jr., Sumanta K. Pal , Biren Saraiya , Lisa M. Cordes , Lisa Ley , Olena Sierra Ortiz , Jacqueline Cadena , Carlos Diaz , Mohammadhadi H. Bagheri , Seth M. Steinberg , Rene Costello , Howard Streicher , John Wright , Howard L. Parnes , Yang-Min Ning , Donald P. Bottaro , Andrea B. Apolo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02496208
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5039)
DOI
10.1200/JCO.2020.38.15_suppl.5039
Abstract #
5039
Poster Bd #
108
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
First Author: Rosa Maria Nadal
Poster
2017 Genitourinary Cancers Symposium
A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.
First Author: Andrea B. Apolo
Poster
2020 ASCO Virtual Scientific Program
Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
First Author: Daniel da Motta Girardi
Poster
2018 ASCO Annual Meeting
Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).
First Author: Rosa Nadal